Artivion Presents New Clinical Data at Annual Thoracic Surgeons Meeting
Artivion announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE IDE trial and its AMDS PERSEVERE IDE trial at the 62nd Annual Meeting of the Society of Thoracic Surgeons in New Orleans, Louisiana. The NEXUS TRIOMPHE IDE trial presentation of 94 patients highlighted 94% patient survival from lesion related death and 91% freedom from disabling stroke at 1-year post-treatment in this high-risk patient group. The data also showed 97% of patients were free from reintervention due to endoleaks with no occurrence of renal failure and one occurrence of paraplegia out to 1-year post-implant. Meanwhile, data from the AMDS PERSEVERE IDE trial demonstrated positive aortic remodeling, minimal morbidity, and zero distal anastomotic new entry, or DANE, tears between 1- and 2-year follow-up. The abstract titled "An Off the Shelf Solution for Chronic Dissections Involving the Aortic Arch: One Year Results of the NEXUS Aortic Arch System" reports 1-year of clinical follow-up on all 94 enrolled patients who were treated with NEXUS for chronic dissection, aneurysm, or other arch disease. The abstract titled "Using a Novel Hybrid Aortic Arch Prosthesis for Open Repair of Acute DeBakey Type I Dissection with Malperfusion: Two-Year Results from the PERSEVERE Trial" reports noteworthy clinical and radiographic outcomes on 93 study participants following 1- and 2-year of clinical and radiographic follow-up.
Trade with 70% Backtested Accuracy
Analyst Views on AORT
About AORT
About the author
HOLX's Innovative AI Mammography Identifies Overlooked Breast Cancer Cases
Clinical Evidence of AI Effectiveness: Hologic, Inc. announced that its Genius AI-based mammography technology significantly improves breast cancer detection, identifying 32% of previously missed cases in a study involving 7,500 exams.
Market Impact and Growth Prospects: Despite a slight decline in shares following the announcement, Hologic's advancements in AI technology are expected to drive long-term growth in the breast health segment, with a market capitalization of $16.76 billion.
AI's Role in Cancer Detection: The AI tool demonstrated high accuracy in localizing suspicious cancer areas, enhancing diagnostic confidence, particularly for invasive ductal cancers, while acknowledging limitations in identifying certain cancer types.
Future Developments and Market Trends: Hologic plans to present new clinical data at an upcoming conference, and the breast cancer diagnostics market is projected to grow significantly, driven by increased awareness and technological innovations.
Artivion Insider Offloads Shares Valued at $576,502, Per Recent SEC Disclosure
Sale of Shares: Jean F Holloway, Senior Vice President and General Counsel, sold 12,787 shares on November 14, 2025.
Portfolio Access: Users need to sign in to access their portfolio information.
Artivion Insider Offloads Shares Valued at $264,188, Based on Recent SEC Disclosure
Stock Sale: Jean F Holloway, Senior Vice President and General Counsel, sold 5,761 shares on November 13, 2025.
Portfolio Access: Users need to sign in to access their portfolio information.
Artivion (AORT): Is the Healthcare Leader Appropriately Priced Following Recent Gains?
Artivion's Performance: Artivion (AORT) has seen a significant share price increase of nearly 60% year-to-date, with a strong 30-day return of over 11%, highlighting its standout performance in the healthcare sector.
Valuation Insights: Analysts suggest that Artivion's fair value is around $45.26, closely aligning with its recent closing price of $44.87, indicating that the market may have already priced in future growth potential.
Growth Opportunities: The ongoing U.S. launch of AMDS, coupled with positive feedback from physicians and a substantial market opportunity, is expected to drive revenue growth and improve EBITDA margins in the long term.
Risks and Market Sentiment: While analysts view Artivion as fairly valued, there are concerns about potential regulatory delays and product adoption issues that could impact growth projections and valuations, with some models suggesting the market may be overly optimistic.
Canaccord Genuity Keeps Buy Rating on Artivion and Increases Price Target to $51
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Artivion Stock: An In-Depth Look at Analyst Opinions (6 Ratings)
Analyst Ratings Overview: In the latest quarter, 6 analysts provided a mix of ratings for Artivion, with 4 bullish, 1 somewhat bullish, and 1 indifferent, reflecting a shift in sentiment over the past 30 days.
Price Target Insights: The average 12-month price target for Artivion has increased to $48.3, surpassing the previous average of $41.67, with estimates ranging from $38.80 to $58.00.
Financial Performance Metrics: Artivion reported a revenue growth rate of approximately 15.26% and a net margin of 1.19%, indicating strong financial health and efficient cost management compared to industry benchmarks.
Company Overview: Artivion Inc specializes in aortic-centric medical solutions, operating primarily in North America, and has two segments: Medical Devices and Preservation Services, with a focus on cardiac and vascular surgical products.
HOLX's Innovative AI Mammography Identifies Overlooked Breast Cancer Cases
Clinical Evidence of AI Effectiveness: Hologic, Inc. announced that its Genius AI-based mammography technology significantly improves breast cancer detection, identifying 32% of previously missed cases in a study involving 7,500 exams.
Market Impact and Growth Prospects: Despite a slight decline in shares following the announcement, Hologic's advancements in AI technology are expected to drive long-term growth in the breast health segment, with a market capitalization of $16.76 billion.
AI's Role in Cancer Detection: The AI tool demonstrated high accuracy in localizing suspicious cancer areas, enhancing diagnostic confidence, particularly for invasive ductal cancers, while acknowledging limitations in identifying certain cancer types.
Future Developments and Market Trends: Hologic plans to present new clinical data at an upcoming conference, and the breast cancer diagnostics market is projected to grow significantly, driven by increased awareness and technological innovations.
Artivion Insider Offloads Shares Valued at $576,502, Per Recent SEC Disclosure
Sale of Shares: Jean F Holloway, Senior Vice President and General Counsel, sold 12,787 shares on November 14, 2025.
Portfolio Access: Users need to sign in to access their portfolio information.
Artivion Insider Offloads Shares Valued at $264,188, Based on Recent SEC Disclosure
Stock Sale: Jean F Holloway, Senior Vice President and General Counsel, sold 5,761 shares on November 13, 2025.
Portfolio Access: Users need to sign in to access their portfolio information.
Artivion (AORT): Is the Healthcare Leader Appropriately Priced Following Recent Gains?
Artivion's Performance: Artivion (AORT) has seen a significant share price increase of nearly 60% year-to-date, with a strong 30-day return of over 11%, highlighting its standout performance in the healthcare sector.
Valuation Insights: Analysts suggest that Artivion's fair value is around $45.26, closely aligning with its recent closing price of $44.87, indicating that the market may have already priced in future growth potential.
Growth Opportunities: The ongoing U.S. launch of AMDS, coupled with positive feedback from physicians and a substantial market opportunity, is expected to drive revenue growth and improve EBITDA margins in the long term.
Risks and Market Sentiment: While analysts view Artivion as fairly valued, there are concerns about potential regulatory delays and product adoption issues that could impact growth projections and valuations, with some models suggesting the market may be overly optimistic.
Canaccord Genuity Keeps Buy Rating on Artivion and Increases Price Target to $51
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Artivion Stock: An In-Depth Look at Analyst Opinions (6 Ratings)
Analyst Ratings Overview: In the latest quarter, 6 analysts provided a mix of ratings for Artivion, with 4 bullish, 1 somewhat bullish, and 1 indifferent, reflecting a shift in sentiment over the past 30 days.
Price Target Insights: The average 12-month price target for Artivion has increased to $48.3, surpassing the previous average of $41.67, with estimates ranging from $38.80 to $58.00.
Financial Performance Metrics: Artivion reported a revenue growth rate of approximately 15.26% and a net margin of 1.19%, indicating strong financial health and efficient cost management compared to industry benchmarks.
Company Overview: Artivion Inc specializes in aortic-centric medical solutions, operating primarily in North America, and has two segments: Medical Devices and Preservation Services, with a focus on cardiac and vascular surgical products.
